Maxime Lafond was born in Roanne, France, in 1990. He received the M.Sc. degree in acoustics from Université du Maine, Le Mans, France, and the Ph.D. degree in biomedical engineering from the LabTAU in 2016, with a focus on unseeded cavitation-based potentiation of doxorubicin, stable cavitation monitoring, and cavitation localization. He held a JSPS post-doctoral fellowship at the Umemura-Yoshizawa Laboratory, Tohoku University, from 2017 to 2018, where he was involved in cavitation monitoring in sonodynamic therapy. He also completed a postdoctoral fellowship at the Image-guided Ultrasound Therapeutics Laboratories, University of Cincinnati, from 2018 to 2021 where he worked on catheter-based ultrasound-mediated drug delivery and bioactive gas delivery for bactericidal and neuroprotective applications. He joined the LabTAU as a research associate (CRCN INSERM) in 2021. His current research interests are in using cavitation for ophthalmologic, cancer, and neuroprotective applications.